$Neovastat (Æ-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels$

Neovastat (Æ-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels

Background: renal cell carcinoma (RCC) is a potential target for anti-angiogenic drugs because of its high vascularization. Neovastat (Æ-941) is an inhibitor of angiogenesis with a mechanism of action that could prove beneficial in the treatment of RCC. Patients and design A phase II trial was condu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2002-08, Vol.13 (8), p.1259-1263
Hauptverfasser:	Batist, G., Patenaude, F., Champagne, P., Croteau, D., Levinton, C., Hariton, C., Escudier, B., Dupont, E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged angiogenesis Angiogenesis Inhibitors - therapeutic use Animals anti-angiogenic agent Antineoplastic agents Biological and medical sciences Carcinoma, Renal Cell - blood supply Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - pathology Cartilage - chemistry Chemotherapy clinical trial Female Humans Key words: Æ-941 Kidney Neoplasms - blood supply Kidney Neoplasms - drug therapy Kidney Neoplasms - pathology Male Medical sciences Middle Aged Neovastat Pharmacology. Drug treatments renal cell carcinoma Sharks Survival Rate Tissue Extracts - adverse effects Tissue Extracts - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!